|
|
Article: Other News To Note.
- Article from:
- BIOWORLD Today
- Article date:
- November 4, 2009
CopyrightCOPYRIGHT 2009 A Thomson Healthcare Company. This material is published under license from the publisher through the Gale Group, Farmington Hills, Michigan. All inquiries regarding rights should be directed to the Gale Group. (Hide copyright information)
|
o AlphaMed Inc., of Acton, Mass., received a $500,000 STTR grant from the National Cancer Institute in Bethesda, Md., to develop a targeted radiotherapy for metastatic melanoma. AlphaMed is collaborating with the University of Missouri in Columbia on work related to the two-year, Phase II award. The therapy is based on a molecule labeled with the therapeutic radionuclide lead-212, which is selective to metastatic melanoma cells. Lead-212 decays to bismuth-212, which in turn emits an alpha particle that is designed to destroy tumor cells on contact.
o AtheroGenics Inc., of Atlanta, is proposing a new issue of $75 million of convertible notes due 2008 to qualified ...
Related newspaper, magazine, and journal articles:
|
|
Article: COMPANY FORGING AHEAD WITH DIABETES DRUG AMYLIN STOCK DROPS 77 ...
BIOWORLD Today;
October 22, 1998 ;
700+ words
... ... price dropped below $8.50. (See BioWorld Today, Aug. 19, 1997, p. 1.) Along ... U.S. and Europe," Krawiec told BioWorld Today. Tanner said Amylin's move to continue ... J $36 million from a loan. (See BioWorld Today, March 3, 1998, p. 1.) Terms ...
|
|